Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. BRZE
2. TTAN
3. AAPL
4. CHYM
5. USO
6. QCOM
7. IRT
8. ASO
9. LAES
10. EVMN

Go back to Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization
(NASDAQ: BJDX) Delayed: 0.97 -0.06 (5.83%)
Previous Close $1.03    52 Week High $ 
Open $1.01    52 Week Low $ 
Day High $1.08    P/E N/A 
Day Low $0.89    EPS $ 
Volume 1,259,915